FDA warns consumers about Que She
This article was originally published in The Tan Sheet
Executive Summary
FDA warns consumers to stop using the weight-loss capsules Que She and consult health care providers because the product contains undeclared active pharmaceutical ingredients that could endanger people with heart conditions. Undeclared ingredients include the Rx weight-loss ingredient sibutramine, which can increase the risk of heart attack and stroke, and the stimulant fenfluramine, which was removed from the U.S. market in 1997 after studies showed it damaged heart valves. The Rx beta blocker propranolol and the stimulant ephedrine also were found in the capsules and pose a risk to people with heart conditions, FDA said July 8. Principal Deputy Commissioner Josh Sharfstein said removing "spiked" supplements from the market is a priority (1"The Tan Sheet" Oct. 26, 2009)
You may also be interested in...
Sharfstein Says Spiked Products Top FDA Supplement Enforcement Goals
FDA Principal Deputy Commissioner Josh Sharfstein says that two to-do lists sit on his desk - one of urgent priorities that the agency must address immediately and one of important tasks that can wait
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.